The inquiry centers on whether the pharmaceutical giant adequately disclosed the extent of its financial exposure and the nature of the semaglutide manufacturing issues to its shareholders. During the company's first-quarter earnings call, CEO Erez Israeli maintained that the batches posed no patient-safety risks and would not affect existing global regulatory filings for the product. These assurances arrived shortly after the company touted several key milestones, including the launch of Obeda in Canada and the approval of oral semaglutide in India.

Levi & Korsinsky is now evaluating whether investors were misled regarding the severity of the production issues before the stock value declined. The firm, which specializes in complex securities litigation, is currently soliciting information from those who purchased shares and sustained losses. Participation in the investigation does not require court appearances or upfront fees, as the firm operates on a contingency basis for aggrieved shareholders.